Dr. Khue Vu Nguyen (born in Ha Noi, Viet Nam) is currently Full Project Scientist in the Departments of Medicine and Pediatrics, University of California, San Diego, School of Medicine, San Diego, California, U.S.A. He has studied at University Louis Pasteur,
Strasbourg, France: B.S. in Biochemistry, M.S. in Molecular Biology, Ph.D. in Macromolecular Physical Chemistry, Ph.D. in Physical Sciences (Doctorat d’Etat es Sciences Physiques). He has worked as Scientist in different French and U.S. Research Institutions and Companies. He is author and co-author of numerous publications and holder of many patents. He is listed in Who’s Who in the World, Who’s Who in America, etc. He is member of different academic organizations such as American Society for Microbiology, American Chemical Society. He is invited reviewer of different scientific journals such as Molecular Genetics and Metabolism, AGE: Journal of the American Aging Association. He is also editorial board member of different
scientific journals such as International Journal of Medicine and Molecular Medicine, Open Journal of Endocrine and Metabolic Diseases. He is Scientist Reviewer for grant proposals of the Metabolic Disease Two (MB-2) of the Peer Review Medical Research Program (PRMRP) for the U.S. Department of Defense Congressionally Directed Medical Research Programs (CDMRP). Current research includes genetic diseases, neurodevelopmental and neurodegenerative disorders, and cancer.
Molecular Biology, Genetic Diseases, Enzymology, Neurodevelopmental and Neurodegenerative Disorders, and Cancer.
Lizhong Wang, Assistant Professor, Department of Genetics, USA
The major focus of my research is on the Molecular Genetics and Epidemiology in cancer and autoimmune disease. I have a broad background in human genetics with more than fifteen years of experience, including specific training and expertise in key research areas. I have identified 1) X-linked tumor suppressor gene FOXP3 and 2) genetic modifier CD24 in human autoimmune diseases. I have published more than 50 original research papers in peer-reviewed journals. Now I am leading independent research program with my collaborators to explore the molecular mechanisms of human diseases.
My research interests focus on human molecular genetics, including cancer and autoimmune diseases. My research group has established the new concept of FOXP3 as the first X-linked tumor suppressor gene in human cancers. In particular, we provided the first evidence that FOXP3 is frequently deleted and mutated in human breast cancer (Cell, 129: 1275-86, 2007), and that FOXP3 is the first X-linked tumor suppressor gene implicated in prostate cancer (Cancer Cell, 16: 336-46, 2009). Recently, we have taken a new research direction, based on our preliminary observations, to pursue innovative projects in identifying microRNA dysregulation and developing genetically engineered mouse models. We will focus on identifying the molecular mechanism of microRNA regulation in tumor cells, which is very important for understanding FOXP3-mediated tumor suppression. Furthermore, we will also utilize new approaches with both forward and reverse genetics to develop more human-like mouse models of prostate cancer, which will aid the search for cancer-causing genes and improve the predictive value of laboratory cancer drug testing. The identification of new human cancer genes and understanding of their role in the formation of tumors will provide a potential avenue to explore new therapeutic strategies. In addition, apart from the tumor suppressor FOXP3, our research also focuses on identifying the functional role of the potential oncogene CD24 in the development and progression of both breast cancer, prostate cancer and multiple sclerosis.
Bhuvnesh K Sharma, University of ScyTek Labs, USA
Preclinical Cancer Research, Cancer Stem Cell Research, Genomic Tumour Pathology,, Diagnostic Immunohistochemistry, Predictive Cancer Tissue Biomarkers, Tumor Immuno-Virology, Companion Cancer Diagnostics, Exploratory Adjuvant Tumor Immunotherapy.
Wenyi (David) Gu, University of Queensland (UQ), Australia
Dr. Wenyi Gu’s early education was conducted in China including his undergraduate and master’s degrees in veterinary medicine. After migration to Australia he pursued his PhD study in biochemistry & molecular biology at the Australian National University. After a year's work at John Curtin Medical School ANU, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a research fellow at AIBN working on drug delivery and cancer therapy using nanotechnology. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow. Before engaging in nanomedicine he worked on RNAi-based therapy for several years. During his research career, he published total 82 journal articles and book chapters including some high-ranked journals such as Nature Communications, Ad. Materials, ACS Nano, PNAS USA et al.
Drug delivery and cancer therapy using nanotechnology.
Jie Ma, Jilin University, China
Benfang Helen Ruan, Zhejiang University of Technology, China
My research interest is to use innovative approaches to discover new drugs for the treatment of cancer and neurological diseases.
We use an integrative approach with multidisciplinary techniques, including molecular biology, bioinformatcs, enzymology, biophysics (e.g. biomolecular interaction analysis), immunochemistry, fluorescence imaging, animal disease model, to evaluate the efficacy of our drug molecules and drug delivery formulation.
Currently, our research is mainly focused on
1) Mitochondrial glutaminolysis. Using state-of-art ForteBio method and novel HTS approaches, we screened and obtained novel chemical scaffolds. Further medicinal chemistry effort provided us with active molecules that effectively inhibited tumor growth in vitro and in vivo. These active molecules then serve as an excellent tool for us to understand the important biological functions of glutaminolysis in tumor metabolism and signaling pathways.
2) Nanotechnology for cancer drug delivery. Applying multidisciplinary techniques, we evaluated biomolecular interactions between nanomaterials and biological systems, with an aim to develop an effective drug delivery approach with good biocompatibility.
Lucio Mango, Department of health services, Italy
Ahmed Abdel Khalek Abdel Razek, Mansoura University, Egypt
His works, as lead author, published more than 90 scientific papers at peer-reviewed high impact journals at pubmed and 40 scientific papers at national journals. He wrote 4 book chapters and presented more than 350 scientific paper and educational exhibit at international meetings of radiology (RSNA, ECR, ASNR, ASHNR and ARRS). He is reviewer at 35 high impact journals and in the editorial board of 7 international journals and societies. He was supervisor on 80 PhD and MD thesis. He won scientific awards from RSNA and ECR during his career.
Research fields are focused on imaging of head and neck cancer, neuro-oncology using advanced magnetic resonance imaging techniques such as diffusion, perfusion, MR spectroscopy and contrast enhanced MR angiography. In addition, he has some work has on role of computed tomography and color Duplex ultrasound in oncology.
Muhammad Saif Ur Rahman, Zhejiang University, China
Biography: Ph.D. Oncology (Clinical Medicine) Clinical Research Center, The Second Affiliated Hospital, Zhejiang University College of Medicine. Zhejiang University, Hangzhou, China.
Researh Interest: Oncology, Molecular Biology
Donghui Zhou, Indiana University School of Medicine, USA
Research Interest: Research focused on the mechanismsregulating a family of eIF2 protein kinases and the physiological advantages this altered pattern of gene expression provides for stressed cells.
Research focused on the development of small molecules to modulate protein-protein interactions that promote cancer invasion and metastasis.
William CS Cho, Queen Elizabeth Hospital, Hong Kong
Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers (Lancet Oncology, Clinical Cancer Research, Clinical Chemistry, Annals of Oncology, etc) covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc.
He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan), etc.
Cancer biomarker, proteomics, microRNA, evidence-based Chinese medicine, diabetes mellitus